[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"meningococcal-immunization\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:meningococcal-immunization":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100639164","post-marketing-surveillance-study-for-menquadfi-meningococcal-groups-a-c-y-w-polysaccharide-tetanus-toxoid-conjugate-vaccine-administered-in-participants-aged-6-weeks-to-55-years-in-republic-of-korea-100639164",false,"NCT07621653","Post Marketing Surveillance Study for MenQuadfi® [Meningococcal (Groups A, C, Y, W) Polysaccharide Tetanus Toxoid Conjugate Vaccine] Administered in Participants Aged 6 Weeks to 55 Years in Republic of Korea","Inclusion Criteria:\n\n* Aged 6 weeks to 55 years on the day of MenQuadfi® vaccination\n* Evidence of a personally signed and dated informed consent document indicating that the participant or their parent(s)\u002Fother legally acceptable representative(s), if applicable, have been informed of all pertinent aspects of the study\n* Participants who have been vaccinated with MenQuadfi® for the first time as per ordinary healthcare setting at the day of inclusion in the study according to the approved local product label\n\nExclusion Criteria:\n\n* Participating or planning participation in any other clinical studies investigating a vaccine, drug, medical device, or medical procedure at the time of the study enrolment (or in 4 weeks preceding the enrolment)\n* Having a previous history of enrollment in this study (participants who have already been enrolled once in this study are not eligible for re-enrollment)\n* Being applicable to contraindications in the approved local product label of MenQuadfi®; anyone with a known systemic hypersensitivity reaction to any component of this vaccine or after previous administration of the vaccine or a vaccine containing the same components\n\nNote: The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.",true,"ALL","6 Weeks","55 Years",{"count":20,"type":21},706,"ESTIMATED","OBSERVATIONAL","This surveillance is to investigate the safety profile of MenQuadfi®, when administered to participants aged 6 weeks to 55 years under the real-world clinical practice settings as per approved indications, including the Adverse Drug Reactions (ADRs)\\*.\n\n\\*It includes ADRs that were not fully recognized in clinical practice, or unexpected ADRs which refer to those not listed in the approved drug labeling.",[25,26],"Meningococcal Immunization","Healthy Volunteers","RECRUITING","2026-07-28",{"date":30,"type":31},"2026-07-29","ACTUAL",{"date":33,"type":31},"2026-07-01",{"date":35,"type":21},"2027-11-23",{"name":37,"class":38},"Sanofi","INDUSTRY",9]